Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
December 03 2021 - 8:00AM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM)
(“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical
company focused on novel technologies including the targeting of
oncological diseases, announced the results of its 2021 annual
general meeting of shareholders, which was held on December 2,
2021, in Hong Kong.
At the annual general meeting, the required number of
shareholders of the Company:
- Re-elected all of the Company’s current directors, namely Mr.
Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst,
Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner
as directors of the Company until the Company’s next annual general
meeting of shareholders or until their respective successors are
duly appointed and qualified;
- Approved, ratified and confirmed the re-appointment of Marcum
Bernstein & Pinchuk LLP as the Company’s independent auditors
for the year ending December 31, 2021 and authorized the Board of
Directors to fix the remuneration of the auditors; and
- Approved, as a special resolution, an amendment to Article 49.1
and Article 49.2 of the Company’s Second Amended and Restated
Memorandum and Articles of Association, which removes the
requirement that the record date not be earlier than the date of
notice of a shareholder meeting and instead, permits Aptorum’s
board of directors more flexibility to set record date deem
suitable, in accordance with the laws of Cayman Islands and those
of the NASDAQ Global Market.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a
clinical stage biopharmaceutical company dedicated to the
discovery, development and commercialization of therapeutic assets
to treat diseases with unmet medical needs, particularly in
oncology (including orphan oncology indications) and infectious
diseases. The pipeline of Aptorum is also enriched through (i) the
establishment of drug discovery platforms that enable the discovery
of new therapeutics assets through, e.g. systematic screening of
existing approved drug molecules, and microbiome-based research
platform for treatments of metabolic diseases; and (ii) the
co-development of a novel molecular-based rapid pathogen
identification and detection diagnostics technology with Accelerate
Technologies Pte Ltd, commercialization arm of the Singapore’s
Agency for Science, Technology and Research.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein. Aptorum Group assumes no
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211203005018/en/
Aptorum Group Limited Investor Relations Department
investor.relations@aptorumgroup.com +44 20 80929299 Redchip –
Financial Communications United States Investor relations Dave
Gentry dave@redchip.com +1 407 491 4498 Actifin – Financial
Communications Europe Investor relations Ghislaine Gasparetto
ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024